Summary

Eligibility
for people ages up to 22 years (full criteria)
Location
at UCSF
Dates
study started
study ends around
Principal Investigator
by Jennifer Michlitsch (ucsf)
Headshot of Jennifer Michlitsch
Jennifer Michlitsch

Description

Summary

A prospective open label, multicenter study to evaluate the feasibility and acute toxicity of using molecularly guided therapy in combination with standard therapy followed by a Randomized Controlled Trial of standard immunotherapy with or without DFMO followed by DFMO maintenance for Subjects with Newly Diagnosed High-Risk Neuroblastoma.

Official Title

A Study Using Molecular Guided Therapy With Induction Chemotherapy Followed by a Randomized Controlled Trial of Standard Immunotherapy With or Without DFMO Followed by DFMO Maintenance for Subjects With Newly Diagnosed High-Risk Neuroblastoma

Keywords

Neuroblastoma, Eflornithine, Sorafenib, Dasatinib, Vorinostat, Ceritinib, DFMO

Eligibility

Locations

  • UCSF Benioff Children's Hospital Oakland- accepting new patients
    Oakland California United States
  • Rady Children's Hospital accepting new patients
    San Diego California 92123 United States

Lead Scientist at University of California Health

  • Jennifer Michlitsch (ucsf)
    Professor, Pediatrics, School of Medicine. Authored (or co-authored) 23 research publications

Details

Status
accepting new patients
Start Date
Completion Date
(estimated)
Sponsor
Giselle Sholler
Links
Beat Childhood Cancer Main Website
ID
NCT02559778
Phase
Phase 2 Neuroblastoma Research Study
Study Type
Interventional
Participants
Expecting 500 study participants
Last Updated